High-throughput identification and rational design of synergistic small-molecule pairs for combating and bypassing antibiotic resistance

PLoS Biology

Volumn 15, Issue 6, 2017, Pages

  Wambaugh, Morgan A ^a   Shakya, Viplendra P S ^a   Lewis, Adam J ^a   Mulvey, Matthew A ^a   Brown, Jessica C S ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; CEFACLOR; CYCLOSPORIN; DAPSONE; DIDANOSINE; EDETIC ACID; EGTAZIC ACID; FLOXURIDINE; HYDROXYUREA; MITOMYCIN; MITOXANTRONE; NOVOBIOCIN; PHTHALYLSULFACETAMIDE; RIFAMPICIN; SULFABENZAMIDE; SULFACETAMIDE; SULFAMETHIZOLE; SULFAPHENAZOLE; SULFAPYRIDINE; TRIMETHOPRIM; VANCOMYCIN; ZIDOVUDINE; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; FOLIC ACID ANTAGONIST; MOLECULAR LIBRARY; RNA DIRECTED DNA POLYMERASE INHIBITOR; URINARY TRACT ANTIINFECTIVE AGENT;

ADENOCARCINOMA; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL LOAD; BACTERIAL VIRULENCE; BRONCHITIS; CONTROLLED STUDY; CRYPTOCOCCUS NEOFORMANS; DNA DAMAGE; DRUG DESIGN; DRUG IDENTIFICATION; DRUG POTENTIATION; EMBRYO; ESCHERICHIA COLI; GROWTH INHIBITION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; MUTATION RATE; NEPHRITIS; NONHUMAN; PREDICTION; URINARY TRACT INFECTION; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; AUTOMATED PATTERN RECOGNITION; BIOASSAY; BIOLOGY; CHEMISTRY; COMBINATION DRUG THERAPY; DRUG EFFECTS; EMBRYOLOGY; ESCHERICHIA COLI INFECTIONS; GENETICS; GROWTH, DEVELOPMENT AND AGING; KLEBSIELLA INFECTIONS; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MOLECULAR LIBRARY; MUTATION; NONMAMMALIAN EMBRYO; VALIDATION STUDY; ZEBRA FISH;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS, URINARY; BACTERIAL PROTEINS; BIOLOGICAL ASSAY; COMPUTATIONAL BIOLOGY; DRUG DESIGN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; EMBRYO, NONMAMMALIAN; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FOLIC ACID ANTAGONISTS; HIGH-THROUGHPUT SCREENING ASSAYS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS; MUTATION; MUTATION RATE; PATTERN RECOGNITION, AUTOMATED; REVERSE TRANSCRIPTASE INHIBITORS; SMALL MOLECULE LIBRARIES; SULFAMETHIZOLE; TRIMETHOPRIM; ZEBRAFISH;

EID: 85021659567     PISSN: 15449173     EISSN: 15457885     Source Type: Journal    
DOI: 10.1371/journal.pbio.2001644     Document Type: Article

References (98)

1. Michael CA, Dominey-Howes D, Labbate M, The antimicrobial resistance crisis: causes, consequences and management. Front Public Health. 2014;2.
2. Prevention CfDCaAntibiotic Resistance Threats in the United States, 2013. Atlanta, USA: U.S. Department of Health and Human Services; 2013.
3. Butts A, Krysan DJ, Antifungal Drug Discovery: Something Old and Something New. PLoS Pathog. 2012;8(9):e1002870. doi: 10.1371/journal.ppat.1002870 22969422
4. Roemer T, Boone C, Systems-level antimicrobial drug and drug synergy discovery. Nat Chem Biol. 2013;9(4):222–31. doi: 10.1038/nchembio.1205 23508188
5. Roemer T, Krysan DJ, Antifungal Drug Development: Challenges, Unmet Clinical Needs, and New Approaches. Cold Spring Harbor Perspectives in Medicine. 2014;4(5).
6. Oprea TI, Mestres J, Drug repurposing: far beyond new targets for old drugs. AAPS J. 2012;14(4):759–63. doi: 10.1208/s12248-012-9390-1 22826034
7. Rangel-Vega A, Bernstein LR, Mandujano-Tinoco EA, García-Contreras SJ, García-Contreras R, Drug repurposing as an alternative for the treatment of recalcitrant bacterial infections. Front Microbiol. 2015;6:282. doi: 10.3389/fmicb.2015.00282 25914685
8. Torella JP, Chait R, Kishony R, Optimal Drug Synergy in Antimicrobial Treatments. PLoS Comput Biol. 2010;6(6):e1000796. doi: 10.1371/journal.pcbi.1000796 20532210
9. Zuo G-Y, Li Y, Wang T, Han J, Wang G-C, Zhang Y-L, et al. Synergistic Antibacterial and Antibiotic Effects of Bisbenzylisoquinoline Alkaloids on Clinical Isolates of Methicillin-Resistant Staphylococcus Aureus (MRSA). Molecules. 2011;16(12):9819–26. doi: 10.3390/molecules16129819 22117171
10. Hill JA, Cowen LE, Using combination therapy to thwart drug resistance. Future Microbiol. 2015;10(11):1719–26. doi: 10.2217/fmb.15.68 26597425
11. Mitchison DA, Prevention of Drug Resistance by Combined Drug Treatment of Tuberculosis. Handb Exp Pharmacol. 2012;211:87–98.
12. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med. 2013;41(2):580–637. doi: 10.1097/CCM.0b013e31827e83af 23353941
13. Paul M, Leibovici L, Combination antimicrobial treatment versus monotherapy: the contribution of meta-analyses. Infect Dis Clin North Am. 2009;23(2):277–93. doi: 10.1016/j.idc.2009.01.004 19393909
14. Tamma PD, Cosgrove SE, Maragakis LL, Combination therapy for treatment of infections with gram-negative bacteria. Clin Microbiol Rev. 2012;25(3):450–70. doi: 10.1128/CMR.05041-11 22763634
15. Ahmed A, Azim A, Gurjar M, Baronia AK, Current concepts in combination antibiotic therapy for critically ill patients. Indian Journal of Critical Care Medicine. 2014;18(5):310–4. doi: 10.4103/0972-5229.132495 24914260
16. Jia J, Zhu F, Ma X, Cao ZW, Li YX, Chen YZ, Mechanisms of drug combinations: interaction and network perspectives. Nat Rev Drug Discov. 2009;8(2):111–28. doi: 10.1038/nrd2683 19180105
17. Tängdén T, Combination antibiotic therapy for multidrug-resistant Gram-negative bacteria. Ups J Med Sci. 2014;119(2):149–53. doi: 10.3109/03009734.2014.899279 24666223
18. Brown JCS, Nelson J, VanderSluis B, Deshpande R, Butts A, Kagan S, et al. Unraveling the biology of a fungal meningitis pathogen using chemical genetics. Cell. 2014;159(5):1168–87. doi: 10.1016/j.cell.2014.10.044 25416953
19. Chandrasekaran S, Cokol-Cakmak M, Sahin N, Yilancioglu K, Kazan H, Collins JJ, et al. Chemogenomics and orthology-based design of antibiotic combination therapies. Mol Syst Biol. 2016;12(5).
20. Robbins N, Spitzer M, Yu T, Cerone Robert P, Averette Anna K, Bahn Y-S, et al. An antifungal combination matrix identifies a rich pool of adjuvant molecules that enhance drug activity against diverse fungal pathogens. Cell Rep. 2015;13(7):1481–92. doi: 10.1016/j.celrep.2015.10.018 26549450
21. Wildenhain J, Spitzer M, Dolma S, Jarvik N, White R, Roy M, et al. Prediction of Synergism from Chemical-Genetic Interactions by Machine Learning. Cell Systems. 2015;1(6):383–95. doi: 10.1016/j.cels.2015.12.003 27136353
22. Pradhan A, Siwo GH, Singh N, Martens B, Balu B, Button-Simons KA, et al. Chemogenomic profiling of Plasmodium falciparum as a tool to aid antimalarial drug discovery. Sci Rep. 2015;5:15930. doi: 10.1038/srep15930 26541648
23. Guiguemde WA, Shelat AA, Bouck D, Duffy S, Crowther GJ, Davis PH, et al. Chemical genetics of Plasmodium falciparum. Nature. 2010;465(7296):311–5. doi: 10.1038/nature09099 20485428
24. Pethe K, Sequeira PC, Agarwalla S, Rhee K, Kuhen K, Phong WY, et al. A chemical genetic screen in Mycobacterium tuberculosis identifies carbon-source-dependent growth inhibitors devoid of in vivo efficacy. Nat Commun. 2010;1(5):1–8.
25. Diezmann S, Michaut M, Shapiro RS, Bader GD, Cowen LE, Mapping the Hsp90 Genetic Interaction Network in Candida albicans Reveals Environmental Contingency and Rewired Circuitry. 2012;8(3):e1002562.
26. Xu D, Sillaots S, Davison J, Hu W, Jiang B, Kauffman S, et al. Chemical genetic profiling and characterization of small-molecule compounds that affect the biosynthesis of unsaturated fatty acids in Candida albicans. J Biol Chem. 2009;284(29):19754–64. doi: 10.1074/jbc.M109.019877 19487691
27. Schwarzmüller T, Ma B, Hiller E, Istel F, Tscherner M, Brunke S, et al. Systematic phenotyping of a large-scale Candida glabrata deletion collection reveals novel antifungal tolerance genes. PLoS Pathog. 2014;10(6):e1004211. doi: 10.1371/journal.ppat.1004211 24945925
28. Nichols RJ, Sen S, Choo YJ, Beltrao P, Zietek M, Chaba R, et al. Phenotypic Landscape of a Bacterial Cell. Cell. 2010;144(1):143–56. doi: 10.1016/j.cell.2010.11.052 21185072
29. Meletiadis J, Pournaras S, Roilides E, Walsh TJ, Defining fractional inhibitory concentration index cutoffs for additive interactions based on self-drug additive combinations, Monte Carlo simulation analysis, and in vitro-in vivo correlation data for antifungal drug combinations against Aspergillus fumigatus. Antimicrob Agents Chemother. 2010;54(2):602–9. doi: 10.1128/AAC.00999-09 19995928
30. Tang J, Wennerberg K, Aittokallio T, What is synergy? The Saariselkä agreement revisited. Front Pharmacol. 2015;6:181. doi: 10.3389/fphar.2015.00181 26388771
31. Takahagi M, Iwasaki H, Nakata A, Shinagawa H, Molecular analysis of the Escherichia coli ruvC gene, which encodes a Holliday junction-specific endonuclease. J Bacteriol. 1991;173(18):5747–53. 1885548
32. Sharples GJ, Lloyd RG, Resolution of Holliday junctions in Escherichia coli: identification of the ruvC gene product as a 19-kilodalton protein. J Bacteriol. 1991;173(23):7711–5. 1657895
33. Byrne RT, Chen SH, Wood EA, Cabot EL, Cox MM, Escherichia coli genes and pathways involved in surviving extreme exposure to ionizing radiation. J Bacteriol. 2014;196(20):3534–45. doi: 10.1128/JB.01589-14 25049088
34. Suzuki Y, Brown GM, The Biosynthesis of Folic Acid: XII. Purification and properties of dihydroneopterin triphosphate pyrophosphohydrolase. J Biol Chem. 1974;249(8):2405–10. 4362677
35. Comer MM, Böck A, Genes for the alpha and beta subunits of the phenylalanyl-transfer ribonucleic acid synthetase of Escherichia coli. J Bacteriol. 1976;127(2):923–33. 783122
36. Menon NK, Robbins J, Peck HD, Chatelus CY, Choi ES, Przybyla AE, Cloning and sequencing of a putative Escherichia coli [NiFe] hydrogenase-1 operon containing six open reading frames. J Bacteriol. 1990;172(4):1969–77. 2180913
37. Lewin CS, Allen RA, Amyes SGB, Antibacterial activity of fluoroquinolones in combination with zidovudine. J Med Microbiol. 1990;33(2):127–31. doi: 10.1099/00222615-33-2-127 2121991
38. Cooper DL, Lovett ST, Toxicity and tolerance mechanisms for azidothymidine, a replication gap-promoting agent, in Escherichia coli. DNA Repair. 2011;10(3):260–70. doi: 10.1016/j.dnarep.2010.11.007 21145792
39. Mamber SW, Brookshire KW, Forenza S, Induction of the SOS response in Escherichia coli by azidothymidine and dideoxynucleosides. Antimicrob Agents Chemother. 1990;34(6):1237–43. 2118327
40. Kristich CJ, Djorić D, Little JL, Genetic basis for vancomycin-enhanced cephalosporin susceptibility in Vancomycin-Resistant Enterococci revealed using counterselection with dominant-negative thymidylate synthase. Antimicrob Agents Chemother. 2014;58(3):1556–64. doi: 10.1128/AAC.02001-13 24366749
41. Donabedian H, Andriole VT, Synergy of Vancomycin with Penicillins and Cephalosporins Against Pseudomonas, Klebsiella, and Serratia. Yale J Biol Med. 1977;50(2):165–76. 408984
42. Becker KW, Skaar EP, Metal limitation and toxicity at the interface between host and pathogen. FEMS Microbiol Rev. 2014;38(6):1235–49. doi: 10.1111/1574-6976.12087 25211180
43. Luo G, Spellberg B, Gebremariam T, Lee H, Xiong YQ, French SW, et al. Combination therapy with iron chelation and vancomycin in treating murine staphylococcemia. Eur J Clin Microbiol Infect Dis. 2014;33(5):845–51. doi: 10.1007/s10096-013-2023-5 24292099
44. Maxwell A, The interaction between coumarin drugs and DNA gyrase. Mol Microbiol. 1993;9(4):681–6. 8231802
45. Coleman MD, Dapsone: modes of action, toxicity and possible strategies for increasing patient tolerance. Br J Dermatol. 1993;129(5):507–13. 8251346
46. Shaaban S, Negm A, Ibrahim EE, Elrazak AA, Chemotherapeutic Agents for the Treatment of Hepatocellular Carcinoma: Efficacy and Mode of Action. Oncol Rev. 2014;8(1):246. doi: 10.4081/oncol.2014.246 25992234
47. Cruz MC, Del Poeta M, Wang P, Wenger R, Zenke G, Quesniaux VFJ, et al. Immunosuppressive and nonimmunosuppressive cyclosporine analogs are toxic to the opportunistic fungal pathogen Cryptococcus neoformans via cyclophilin-dependent inhibition of calcineurin. Antimicrob Agents Chemother. 2000;44(1):143–9. 10602736
48. Yarchoan R, Pluda JM, Perno CF, Mitsuya H, Thomas RV, Wyvill KM, et al. Initial clinical experience with dideoxynucleosides as single agents and in combination therapy. Ann N Y Acad Sci. 1990;616(1):328–43.
49. Chu CK, Baker DC, Nucleosides and nucleotides as antitumor and antiviral agents. New York, USA: Springer Science and Business Media; 1993.
50. Elwell LP, Ferone R, Freeman GA, Fyfe JA, Hill JA, Ray PH, et al. Antibacterial activity and mechanism of action of 3'-azido-3'-deoxythymidine (BW A509U). Antimicrob Agents Chemother. 1987;31(2):274–80. 3551832
51. Seier T, Zilberberg G, Zeiger DM, Lovett ST, Azidothymidine and other chain terminators are mutagenic for template-switch-generated genetic mutations. Proc Natl Acad Sci U S A. 2012;109(16):6171–4. doi: 10.1073/pnas.1116160109 22474374
52. Hitchings GH, Singleton SW, Trimethoprim/sulfonamide: rational combination therapy. Comprehensive Therapy. 1976;2(5):55–63. 776520
53. Janion C, Inducible SOS response system of DNA repair and mutagenesis in Escherichia coli. Int J Biol Sci. 2008;4(6):338–44. 18825275
54. Tomasz M, Mitomycin C: small, fast and deadly (but very selective). Chem Biol. 1995;2(9):575–9. 9383461
55. Crowley DJ, Hanawalt PC, Induction of the SOS response increases the efficiency of global nucleotide excision repair of cyclobutane pyrimidine dimers, but not 6–4 photoproducts, in UV-irradiated Escherichia coli. 1998;180(13):3345–52. 9642186
56. Davies BW, Kohanski MA, Simmons LA, Winkler JA, Collins JJ, Walker GC, Hydroxyurea induces hydroxyl radical-mediated cell death in Escherichia coli. Mol Cell. 2009;36(5):845–60. doi: 10.1016/j.molcel.2009.11.024 20005847
57. Luria SE, Delbruck M, Mutations of Bacteria from virus sensitivity to virus resistance. Genetics. 1943;28(6):491–511. 17247100
58. Komp Lindgren P, Karlsson Å, Hughes D, Mutation rate and evolution of fluoroquinolone resistance in Escherichia coli isolates from patients with urinary tract infections. Antimicrob Agents Chemother. 2003;47(10):3222–32. doi: 10.1128/AAC.47.10.3222-3232.2003 14506034
59. Boe L, Tolker-Nielsen T, Eegholm KM, Spliid H, Vrang A, Fluctuation analysis of mutations to nalidixic acid resistance in Escherichia coli. J Bacteriol. 1994;176(10):2781–7. 8188580
60. Hall BM, Ma C, Liang P, Singh KK, Fluctuation AnaLysis CalculatOR (FALCOR): a web tool for the determination of mutation rate using Luria-Delbruck fluctuation analysis. Bioinformatics. 2009;25(12):1564–65. doi: 10.1093/bioinformatics/btp253 19369502
61. Quinlivan EP, McPartlin J, Weir DG, Scott J, Mechanism of the antimicrobial drug trimethoprim revisited. FASEB J. 2000;14(15):2519–24. doi: 10.1096/fj.99-1037com 11099470
62. Ferla MP, Patrick WM, Bacterial methionine biosynthesis. Microbiology. 2014;160(8):1571–84.
63. Uchikubo Y, Hasegawa T, Mitani S, Kim H-S, Wataya Y, Mechanisms of cell death induced by 5-fluoro-2′-deoxyuridine (FUdR)—Necrosis or apoptosis after treated with FUdR. Nucleic Acids Res Suppl. 2002;2(1):245–6.
64. O'Donovan GA, Edlin G, Fuchs JA, Neuhard J, Thomassen E, Deoxycytidine triphosphate deaminase: characterization of an Escherichia coli mutant deficient in the enzyme. J Bacteriol. 1971;105(2):666–72. 5541540
65. Neuhard J, Thomassen E, Altered deoxyribonucleotide pools in P2 eductants of Escherichia coli K-12 due to deletion of the dcd gene. J Bacteriol. 1976;126(2):999–1001. 177407
66. Schaaper RM, Mathews CK, Mutational consequences of dNTP pool imbalances in E. coli. DNA Repair. 2013;12(1):73–9. doi: 10.1016/j.dnarep.2012.10.011 23218950
67. Hama H, Almaula N, Lerner CG, Inouye S, Inouye M, Nucleoside diphosphate kinase from Escherichia coli; its overproduction and sequence comparison with eukaryotic enzymes. Gene. 1991;105(1):31–6. 1657712
68. Lu Q, Zhang X, Almaula N, Mathews CK, Inouye M, The gene for nucleoside diphosphate kinase functions as a mutator gene in Escherichia coli. J Mol Biol. 1995;254(3):337–41. doi: 10.1006/jmbi.1995.0620 7490752
69. Cokol M, Chua HN, Tasan M, Mutlu B, Weinstein ZB, Suzuki Y, et al. Systematic exploration of synergistic drug pairs. Mol Syst Biol. 2011;7:544. doi: 10.1038/msb.2011.71 22068327
70. Spitzer M, Griffiths E, Blakely KM, Wildenhain J, Ejim L, Rossi L, et al. Cross-species discovery of syncretic drug combinations that potentiate the antifungal fluconazole. Mol Syst Biol. 2011;7.
71. Tobin DM, May RC, Wheeler RT, Zebrafish: A see-through host and a fluorescent toolbox to probe host—pathogen interaction. PLoS Pathog. 2012;8(1):e1002349. doi: 10.1371/journal.ppat.1002349 22241986
72. Tenor JL, Oehlers SH, Yang JL, Tobin DM, Perfect JR, Live Imaging of Host-Parasite Interactions in a Zebrafish Infection Model Reveals Cryptococcal Determinants of Virulence and Central Nervous System Invasion. mBio. 2015;6(5):e01425–15. doi: 10.1128/mBio.01425-15 26419880
73. Walton EM, Cronan MR, Beerman RW, Tobin DM, The macrophage-specific promoter mfap4 allows live, long-term analysis of macrophage behavior during mycobacterial infection in zebrafish. PLoS ONE. 2015;10(10):e0138949. doi: 10.1371/journal.pone.0138949 26445458
74. Brothers KM, Newman ZR, Wheeler RT, Live Imaging of Disseminated Candidiasis in Zebrafish Reveals Role of Phagocyte Oxidase in Limiting Filamentous Growth. Eukaryot Cell. 2011;10(7):932–44. doi: 10.1128/EC.05005-11 21551247
75. Wiles TJ, Bower JM, Redd MJ, Mulvey MA, Use of Zebrafish to Probe the Divergent Virulence Potentials and Toxin Requirements of Extraintestinal Pathogenic Escherichia coli. PLoS Pathog. 2009;5(12):e1000697. doi: 10.1371/journal.ppat.1000697 20019794
76. Eimon PM, Rubinstein AL, The use of in vivo zebrafish assays in drug toxicity screening. Expert Opin Drug Metab Toxicol. 2009;5(4):393–401. doi: 10.1517/17425250902882128 19368493
77. Raldúa D, Piña B, In vivo zebrafish assays for analyzing drug toxicity. Expert Opin Drub Metab Toxicol. 2014;10(5):685–97.
78. Barber AE, Fleming BA, Mulvey MA, Similarly lethal strains of extraintestinal pathogenic Escherichia coli trigger markedly diverse host responses in a zebrafish model of sepsis. mSphere. 2016;1(2):e00062–16. doi: 10.1128/mSphere.00062-16 27303721
79. May DB, Hooper DC, Trimethoprim-sulfamethoxazole: An overview. Waltham, MA2017.
80. LexicompZidovudine: Drug Information. Waltham, MA2017.
81. Zeitlinger MA, Derendorf H, Mouton JW, Cars O, Craig WA, Andes D, et al. Protein Binding: Do We Ever Learn?Antimicrob Agents Chemother. 2011;55(7):3067–74. doi: 10.1128/AAC.01433-10 21537013
82. Lee AY, St.Onge RP, Proctor MJ, Wallace IM, Nile AH, Spagnuolo PA, et al. Mapping the cellular response to small molecules using chemogenomic fitness signatures. Science. 2014;344(6180):208–11. doi: 10.1126/science.1250217 24723613
83. Yeh PJ, Hegreness MJ, Aiden AP, Kishony R, Drug interactions and the evolution of antibiotic resistance. Nat Rev Micro. 2009;7(6):460–6.
84. Zimmermann GR, Lehár J, Keith CT, Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today. 2007;12(1–2):34–42. doi: 10.1016/j.drudis.2006.11.008 17198971
85. Typas A, Sourjik V, Bacterial protein networks: properties and functions. Nat Rev Micro. 2015;13(9):559–72.
86. Wang G, Wilson TJM, Jiang Q, Taylor DE, Spontaneous mutations that confer antibiotic resistance in Helicobacter pylori. Antimicrob Agents Chemother. 2001;45(3):727–33. doi: 10.1128/AAC.45.3.727-733.2001 11181351
87. Gustafsson I, Sjölund M, Torell E, Johannesson M, Engstrand L, Cars O, et al. Bacteria with increased mutation frequency and antibiotic resistance are enriched in the commensal flora of patients with high antibiotic usage. J Antimicrob Chemother. 2003;52(4):645–50. doi: 10.1093/jac/dkg427 12972454
88. Gustafsson I, Sjolund M, Torell E, Johannesson M, Engstrand L, Cars O, et al. Bacteria with increased mutation frequency and antibiotic resistance are enriched in the commensal flora of patients with high antibiotic usage. J Antimicrob Chemother. 2003;52:645–50. doi: 10.1093/jac/dkg427 12972454
89. Fuentes-Hernandez A, Plucain J, Gori F, Pena-Miller R, Reding C, Jansen G, et al. Using a Sequential Regimen to Eliminate Bacteria at Sublethal Antibiotic Dosages. PLoS Biol. 2015;13(4):e1002104. doi: 10.1371/journal.pbio.1002104 25853342
90. Hegreness M, Shoresh N, Damian D, Hartl D, Kishony R, Accelerated evolution of resistance in multidrug environments. Proceedings of the National Academy of Sciences of the United States of America. 2008;105(37):13977–81. doi: 10.1073/pnas.0805965105 18779569
91. Jain S, Mayer KH, Practical guidance for nonoccupational postexposure prophylaxis to prevent HIV infection: an editorial review. AIDS. 2014;28(11):1545–54. doi: 10.1097/QAD.0000000000000301 24785956
92. Hsieh MH, Yu CM, Yu VL, Chow JW, Synergy assessed by checkerboard: a critical analysis. Diagnostic Microbiology and Infectious Disease. 1993;16(4):343–9. 8495592
93. Datsenko KA, Wanner BL, One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products. Proc Natl Acad Sci U S A. 2000;97(12):6640–5. doi: 10.1073/pnas.120163297 10829079
94. Russell CW, Mulvey MA, The extraintestinal pathogenic Escherichia coli factor RqlI constrains the genotoxic effects of the RecQ-like helicase RqlH. PLoS Pathog. 2015;11(12):e1005317. doi: 10.1371/journal.ppat.1005317 26636713
95. Stehr CM, Linbo TL, Incardona JP, Scholz NL, The Developmental Neurotoxicity of Fipronil: Notochord Degeneration and Locomotor Defects in Zebrafish Embryos and Larvae. Toxicol Sci. 2006;92(1):270–8. doi: 10.1093/toxsci/kfj185 16611622
96. McEvoy GKe, American Hospital Formulary Service—Drug Information 2003. Bethesda, MD2003.
97. Young LY, Koda-Kimble MAe, Vancouver WA, Applied Therapeutics. The Clinical Use of Drugs. 6th ed. Applied Therapeutics, Inc.; 1995.
98. McEvoy GKe, American Hospital Formulary Service—Drug Information 97. Bethesda, MD: American Society of Health-System Pharmacists, Inc.; 1997.